T-cell receptor (TCR) therapy is a rapidly emerging adaptive cell therapy (ACT) method in the field of cancer immunotherapy. However, the process for developing effective T-cell receptors can be time consuming, particularly with regard to the rigorous functional testing needed prior to scale-up and patient infusion.
In this webinar, Stephen Schoenberger of the La Jolla Institute for Immunology discusses how he is leveraging an automated DNA assembly and cloning platform, the BioXp 3200, to achieve a 10-fold increase in the development of TCRs.
